Literature DB >> 9428349

Proteases and their inhibitors in human brain tumours: a review.

H K Rooprai1, D McCormick.   

Abstract

Proteases such as matrix metalloproteinases (MMPs), cysteine- and serine-proteinases are capable of degrading extracellular matrix and basement membranes and have been implicated in human brain tumours. MMPs are a homologous family of zinc-dependent proteases. Within this group, attention has been focused on the gelatinases (MMP-2 and MMP-9) which are thought to play an important role in tumour progression. The cysteine proteinases which have received most attention in relation to tumour progression are cathepsin B (CB) and to a lesser extent cathepsin L (CL). Among the serine proteinases, urokinase plasminogen activator and its receptor have been the subject of much investigation. In the present review, evidence from current literature on the possible role or significance of serine- and cysteine-proteinases and MMPs and their inhibitors in human brain tumours is discussed with special reference to gliomas. Although direct evidence is reported for MMPs and serine proteinases to support their role in glioma invasion, much of the evidence for the involvement of cysteine proteinases remains circumstantial.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9428349

Source DB:  PubMed          Journal:  Anticancer Res        ISSN: 0250-7005            Impact factor:   2.480


  34 in total

Review 1.  Multi-agent cytostatic treatment of 'low-grade' gliomas.

Authors:  M E Linskey
Journal:  Curr Oncol Rep       Date:  2000-09       Impact factor: 5.075

Review 2.  Molecular optical imaging: applications leading to the development of present day therapeutics.

Authors:  Khalid Shah; Ralph Weissleder
Journal:  NeuroRx       Date:  2005-04

Review 3.  Biology of angiogenesis and invasion in glioma.

Authors:  Matthew C Tate; Manish K Aghi
Journal:  Neurotherapeutics       Date:  2009-07       Impact factor: 7.620

Review 4.  Matrix metalloproteinases in the adult brain physiology: a link between c-Fos, AP-1 and remodeling of neuronal connections?

Authors:  Leszek Kaczmarek; Joanna Lapinska-Dzwonek; Sylwia Szymczak
Journal:  EMBO J       Date:  2002-12-16       Impact factor: 11.598

5.  Cancer stem cells from a rare form of glioblastoma multiforme involving the neurogenic ventricular wall.

Authors:  Shengwen Calvin Li; Long T Vu; Hector W Ho; Hong Zhen Yin; Vic Keschrumrus; Qiang Lu; Jun Wang; Heying Zhang; Zhiwei Ma; Alexander Stover; John H Weiss; Philip H Schwartz; William G Loudon
Journal:  Cancer Cell Int       Date:  2012-09-20       Impact factor: 5.722

Review 6.  The role of matrix metalloproteinase genes in glioma invasion: co-dependent and interactive proteolysis.

Authors:  T E VanMeter; H K Rooprai; M M Kibble; H L Fillmore; W C Broaddus; G J Pilkington
Journal:  J Neurooncol       Date:  2001-06       Impact factor: 4.130

Review 7.  Biological mechanisms of glioma invasion and potential therapeutic targets.

Authors:  B B Tysnes; R Mahesparan
Journal:  J Neurooncol       Date:  2001-06       Impact factor: 4.130

8.  Profiling of differentially expressed genes in human gastric carcinoma by cDNA expression array.

Authors:  Lian-Xin Liu; Zhi-Hua Liu; Hong-Chi Jiang; Xin Qu; Wei-Hui Zhang; Lin-Feng Wu; An-Long Zhu; Xiu-Qin Wang; Min Wu
Journal:  World J Gastroenterol       Date:  2002-08       Impact factor: 5.742

9.  Sphingosine-1-phosphate and interleukin-1 independently regulate plasminogen activator inhibitor-1 and urokinase-type plasminogen activator receptor expression in glioblastoma cells: implications for invasiveness.

Authors:  Lauren Bryan; Barbara S Paugh; Dmitri Kapitonov; Katarzyna M Wilczynska; Silvina M Alvarez; Sandeep K Singh; Sheldon Milstien; Sarah Spiegel; Tomasz Kordula
Journal:  Mol Cancer Res       Date:  2008-09       Impact factor: 5.852

10.  The invasiveness of five medulloblastoma cell lines in collagen gels.

Authors:  Adrianna Ranger; Warren McDonald; Emi Moore; Rolando Delmaestro
Journal:  J Neurooncol       Date:  2009-07-15       Impact factor: 4.130

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.